Synergy of strains that accelerate biodegradation of pyridine and quinoline.

J Environ Manage

Biodesign Swette Center for Environmental Biotechnology, Arizona State University, Tempe, AZ85287-5701, USA.

Published: May 2021

AI Article Synopsis

Article Abstract

Three bacterial strains were isolated from activated sludge acclimated to biodegrade pyridine and quinoline simultaneously. The strains were identified as Bacillus tropicus, Bacillus aquimaris, and Rhodococcus ruber. When the isolated bacteria were used for pyridine and quinoline biodegradation in separate or combined modes, R. ruber had much faster kinetics, and combining R. ruber with one or both of the Bacillus strains increased further the biodegradation kinetics. For example, the time needed for complete biodegradation of 1 mM quinoline and pyridine decreased to 20 h and 6 h, respectively, with the three strains combined, compared to 26 h and 7 h with R. ruber alone. Whereas quinoline was completely mineralized by all three strains, 10-14% of the pyridine persisted as a dead-end product, 2-hydroxypyridine (2HP). The acclimated sludge from which the three bacterial species were isolated was able to transform 2HP, and adding the bacterial strains (especially R. ruber) to the acclimated sludge accelerated the rate of 2HP removal and mineralization through a form of synergy.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jenvman.2021.112119DOI Listing

Publication Analysis

Top Keywords

pyridine quinoline
12
three bacterial
8
bacterial strains
8
three strains
8
acclimated sludge
8
strains
6
pyridine
5
quinoline
5
ruber
5
synergy strains
4

Similar Publications

Pre-Clinical Rationale for Amcenestrant Combinations in HER2+/ER+ Breast Cancer.

Int J Mol Sci

January 2025

Cancer Biotherapeutics Research Group, Life Sciences Institute, School of Biotechnology, Dublin City University, Dublin 9, D09 NR58 Dublin, Ireland.

HER2-positive/oestrogen receptor-positive (HER2+/ER+) represents a unique breast cancer subtype. The use of individual HER2- or ER-targeting agents can lead to the acquisition of therapeutic resistance due to compensatory receptor crosstalk. New drug combinations targeting HER2 and ER could improve outcomes for patients with HER2+/ER+ breast cancer.

View Article and Find Full Text PDF

Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the gene. Currently, CFTR modulators are the most effective treatment for CF; however, they may not be suitable for all patients. A representative and convenient model is needed to screen therapeutic agents under development.

View Article and Find Full Text PDF

Transition-metal-catalyzed selective and efficient activation of an inert C-H bond in an organic substrate is of importance for the development of streamlined synthetic methodologies. An attractive approach is the design of a metal catalyst capable of recognizing an organic substrate through noncovalent interactions to control reactivity and selectivity. We report here a spirobipyridine ligand that bears a hydroxy group that recognizes pyridine and quinoline substrates through hydrogen bonding, and in combination with an iridium catalyst enables site-selective C-H borylation.

View Article and Find Full Text PDF

This retrospective population-based study investigated the impact of elexacaftor/tezacaftor/ivacaftor (ETI) therapy on inhaled medication adherence in people with cystic fibrosis (pwCF). Prescription refill rate (PRR) for several inhaled medications were compared before and after ETI introduction in three major Italian CF centers. We found a significant decrease in PRR for most inhaled antibiotics and dornase-alpha after ETI implementation.

View Article and Find Full Text PDF

Clinical trials demonstrate the short-term efficacy of dual CFTR modulators, but long-term real-world data is limited. We aimed to investigate the effects of 24-month lumacaftor/ivacaftor (LUM/IVA) therapy in pediatric CF patients (pwCF). This observational study included pwCF homozygous for F508del mutation treated between 2021 and 2023.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!